Federal Register / Vol. 88, No. 211 / Thursday, November 2, 2023 / Notices 75287 

Injury Prevention and Control, Centers 

for Disease Control and Prevention, 

4770 Buford Highway NE, Mailstop 

S106–9, Atlanta, Georgia 30341. 

Telephone: (404) 639–0913; Email: 

MWalters@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2023–24242 Filed 11–1–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)– 

CE24–030, Research Grants for 

Preventing Violence and Violence 

Related Injury (R01). 

Dates: April 2–3, 2024. 

Times: 8:30 a.m.–5 p.m., EDT. 

Place: Videoconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Carlisha Gentles, Pharm.D., B.C.P.S., 

C.D.C.E.S., Scientific Review Officer, 

National Center for Injury Prevention 

and Control, Centers for Disease Control 

and Prevention, 4770 Buford Highway 

NE, Mailstop F–63, Atlanta, Georgia 

30341. Telephone: (770) 488–1504; 

Email: CGentles@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2023–24241 Filed 11–1–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)– 

CE22–003, Rigorously Evaluating 

Programs and Policies to Prevent Child 

Sexual Abuse (CSA). 

Date: April 11, 2024. 

Time: 8:30 a.m.–5 p.m., EDT. 

Place: Videoconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Mikel L. Walters, Ph.D., Scientific 

Review Officer, National Center for 

Injury Prevention and Control, Centers 

for Disease and Prevention, 4770 Buford 

Highway NE, Mailstop S106–9, Atlanta, 

Georgia 30341. Telephone: (404) 639– 

0913; Email: MWalters@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2023–24239 Filed 11–1–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)– 

CE24–012, Rigorous Evaluation of 

Policy-Level Interventions to Prevent 

Overdose. 

Date: March 26, 2024. 

Time: 8:30 a.m.–5 p.m., EDT. 

Place: Videoconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Aisha L. Wilkes, M.P.H., Scientific 

Review Officer, National Center for 

Injury Prevention and Control, Centers 

for Disease Control and Prevention, 

4770 Buford Highway NE, Mailstop 

S106–9, Atlanta, Georgia 30341. 

Telephone (404) 639–6473; Email: 

AWilkes@cdc.gov. 


khammond on DSKJM1Z7X2PROD with NOTICES